Scholar Rock Holding Corporation · NASDAQ:SRRK
Scholar Rock — Q3 2026 Earnings Presentation
27 slides from Scholar Rock's earnings presentation, Nov 10, 2026
Slide 1: Q3 2026 Earnings Call
Q3 2026 Earnings Call November 10, 2026 © 2026 Scholar Rock, Inc. All rights reserved.
Slide 2: Q3 2026 Earnings Call agenda and presenters
SMA, Spinal Muscular Atrophy. © 2026 Scholar Rock, Inc. All rights reserved. Q3 2026 Earnings Call 01 02 03 04 05 BUSINESS OVERVIEW David L. Hallal Chairman & Chief Executive Officer COMMERCIAL UPDATE Keith Woods Chief Operating Officer R&D PROGRESS Akshay Vaishnaw, M.D., Ph.D. President of R&D FINA
Slide 3: Forward-Looking Statements
Forward-Looking Statements © 2026 Scholar Rock, Inc. All rights reserved. This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans
Slide 4: Business Overview
Business Overview David L. Hallal Chairman & Chief Executive Officer © 2026 Scholar Rock, Inc. All rights reserved.
Slide 5: Building the next global biotech powerhouse
© 2026 Scholar Rock, Inc. All rights reserved. BUILDING THE NEXT GLOBAL BIOTECH POWERHOUSE FDA APPROVED NOW First and only muscle-targeted therapy for adults and children ≥2 years of age with SMA U.S. Launch Underway Apitegromab MAA in Europe: Resubmitted MAA for treatment of children and adults wit
Slide 6: ISEMBYLD is ushering in next phase of innovation in SMA
ISEMBYLD™ is ushering in next phase of innovation in SMA © 2026 Scholar Rock, Inc. All rights reserved. 93% OF PATIENTS said gaining muscle strength is a significant unmet need in a 2026 Cure SMA survey1 ~3/4 recognize the future of treatment targets the motor neuron AND the muscle2 OF NEUROLOGISTS
Slide 7: ISEMBYLD indicated for SMA; U.S. launch underway
© 2026 Scholar Rock, Inc. All rights reserved. ISEMBYLD™ (apitegromab-mstn) is indicated for the treatment of spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment1 U.S. LAUNCH NOW UNDERWAY LOSS O
Slide 8: Broad-based demand in the earliest phase of launch
Broad-based demand in the earliest phase of launch as measured by volume and breadth of prescribers and patients As of October 31, 2026. © 2026 Scholar Rock, Inc. All rights reserved. SITES PRESCRIBING ISEMBYLD of Top 140 SMA treatment centers enrolled initial patients >1/3 all geographies nationwid
Slide 9: Opportunity to serve a steady number of new patients
9 Opportunity to serve a steady and consistent number of new patients for quarters and years to come.
Slide 10: Commercial Update
Commercial Update Keith Woods Chief Operating Officer © 2026 Scholar Rock, Inc. All rights reserved.
Slide 11: U.S. SMA opportunity
1. Data provided by Cure SMA U.S. SMA OPPORTUNITY FDA APPROVED NOW ISEMBYLD™ positioned to redefine the standard-of-care in SMA ~6,600 patients have received an approved SMN2-targeted therapy1 © 2026 Scholar Rock, Inc. All rights reserved.
Slide 12: Executed key ISEMBYLD launch priorities in September
© 2026 Scholar Rock, Inc. All rights reserved. Executed key ISEMBYLD™ launch priorities in September upon FDA approval ISEMBYLD vials labeled, packaged, and shipped to specialty network within one week Scholar Rock Supports immediately began working with physicians and families for initial patients
Slide 13: Patient and caregiver awareness and engagement is high
Patient and caregiver awareness and engagement is high Registered for ISEMBYLD webinars ~1,000 PATIENTS & CAREGIVERS Email opt-ins from patients, caregivers and HCPs for ISEMBYLD communications 10,000 © 2026 Scholar Rock, Inc. All rights reserved. Extensive field team reach to Top 140 centers in U.S
Slide 14: Broad-based demand in the earliest phase of launch
Broad-based demand in the earliest phase of launch as measured by volume and breadth of prescribers and patients As of October 31, 2026. © 2026 Scholar Rock, Inc. All rights reserved. SITES PRESCRIBING ISEMBYLD of Top 140 SMA treatment centers enrolled initial patients >1/3 all geographies nationwid
Slide 15: Facilitating a clear path from prescription to infusion
Facilitating a clear path from prescription to infusion Broad and reliable access to ISEMBYLD™ to be established over time © 2026 Scholar Rock, Inc. All rights reserved. ISEMBYLD-SPECIFIC J-CODE PAYER POLICIES ESTABLISHED HOSPITAL FORMULARY APPROVALS PRIOR AUTHORIZATION PROCESS Key Factors Required
Slide 16: 98% of patients enrolling in Scholar Rock Supports
98% of patients are enrolling in Scholar Rock Supports to assist with the treatment journey Source: Scholar Rock Supports. ROCC, Rx Onboarding and Care Coordinator. © 2026 Scholar Rock, Inc. All rights reserved. Providing personalized, dedicated support from prescription to infusion, which can take
Slide 17: Working to bring to SMA patients globally
WORKING TO BRING TO SMA PATIENTS GLOBALLY Building a 50-country operating platform to serve patients with rare, severe neuromuscular diseases UNITED STATES EUROPE REST OF WORLD Pending regulatory approvals outside the United States. © 2026 Scholar Rock, Inc. All rights reserved. JAPAN 17
Slide 18: R&D Progress
R&D Progress Akshay Vaishnaw, M.D., Ph.D. President of R&D © 2026 Scholar Rock, Inc. All rights reserved.
Slide 19: Scholar Rock R&D priorities
Scholar Rock R&D priorities © 2026 Scholar Rock, Inc. All rights reserved. To enable treatment for children and adults with SMA in up to 50 countries worldwide SECURE GLOBAL APITEGROMAB REGULATORY APPROVALS Subcutaneous apitegromab, SMA patients <2 years of age, and new indications ADVANCE APITEGROM
Slide 20: Securing regulatory approvals in up to 50 countries
Securing regulatory approvals to bring apitegromab to children and adults with SMA in up to 50 countries globally MAA, Marketing Authorisation Application; EMA, European Medicines Agency; JNDA, Japanese New Drug Application; PMDA, Japan Pharmaceuticals and Medical Devices Agency. Europe Japan MAA re
Slide 21: Advancing apitegromab clinical development programs
Advancing apitegromab clinical development programs Subcutaneous apitegromab and apitegromab have not been approved for the indications and uses discussed on this slide by the FDA or any other regulatory agency. © 2026 Scholar Rock, Inc. All rights reserved. PHASE 1 STUDY COMPLETE Subcutaneous Apite
Slide 22: Progressing SRK-439, next generation anti-myostatin program
© 2026 Scholar Rock, Inc. All rights reserved. Progressing SRK-439, our next generation anti-myostatin program PHASE 1 STUDY SRK-439 High potency, high affinity, investigational, subcutaneously administered myostatin inhibitor Enrollment and dosing ongoing On track to report topline data in early 20
Slide 23: Financial Update
Financial Update Vikas Sinha Chief Financial Officer © 2026 Scholar Rock, Inc. All rights reserved.
Slide 24: Q3 2026 Financial Results: Operating from a position of strength
Q3 2026 Financial Results: Operating from a position of strength © 2026 Scholar Rock, Inc. All rights reserved. Reported $0.6 million in Q3, reflecting initial ISEMBYLD inventory shipments 1 Definitive agreement signed to sell Priority Review Voucher for additional $205 million* 2 Additional $150 mi
Slide 25: Closing Remarks
Closing Remarks David L. Hallal Chairman & Chief Executive Officer © 2026 Scholar Rock, Inc. All rights reserved.
Slide 26: Q&A
Q&A © 2026 Scholar Rock, Inc. All rights reserved.
Slide 27: Thank You
ir@scholarrock.com media@scholarrock.com www.scholarrock.com THANK YOU © 2026 Scholar Rock, Inc. All rights reserved.